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Objectives: To establish the key drivers of purchasing, pricing, access, and 
profitability for biologics in markets where biosimilars, bio-originals, and new 
innovative biologics compete. To provide insight into how sustainability, profit, 
pricing and access are driven by differentiation. MethOds: A meta-analysis 
was conducted across all studies (n= 14) undertaken by GfK since January 2014 
involving the pricing and market access of biologics in Europe in inflammatory 
disease and oncology. The studies involved primary research, system dynamics 
modelling, and war gaming (competitive simulation). Primary research com-
prised interviews (n= 250) across 7 European markets: France, Germany, Hungary, 
Italy, Poland, Spain and the UK, collecting insight at pan-European, National and 
Regional levels, Physicians, Payers, Patients, and Industry. System dynamics mod-
elling, based on delphi panels of expert opinion, focused on 2 oncology products 
(trastuzumab, bevacizumab) and 3 anti-TNFs (infliximab, etanercept, adalimumab). 
War gaming was used to explore the forces of supplier and buyer power, impact 
of new entrants, impact of substitutes, and competitive rivalry. The impact of 
price referencing was included in the analysis, as was consideration of parallel 
trade. Results: The analysis showed that the key drivers of purchasing, access, 
and profitability in markets where biosimilars compete are product differentiation, 
relative effective net pricing, and multi-criteria decision-making. Both sustain-
ability and profitability are driven by differentiation. War gaming indicates that 
a market that recognizes these drivers and dynamics will deliver benefits to all 
stakeholders, including the opportunity for cost savings that can be used to fund 
access to the next generation of innovative new high cost / high value thera-
pies. cOnclusiOns: Acceptance of multi-criteria decision making that includes 
non-price criteria, a willingness to pay for differentiation, and the evolution of 
policies relating to interchangeability, substitution and switching will increase 
the stability, sustainability and profitability of markets that include biosimilars.
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Objectives: Medication persistence and adherence are important to treat-
ment success, particularly where target level achievement is critical, as in gout. 
Identifying barriers provides opportunity to improve patient outcomes. The objec-
tive is to evaluate persistence and adherence of allopurinol (ALLO) new users as 
well as relation to clinical determinants. MethOds: We assessed profile of ALLO 
use among a cohort of new ALLO users after starting an antihypertensive agents, 
using RAMQ and MED-ECHO Québec administrative databases. New ALLO users 
aged 45-85 yrs with ≥ 1 claim from Jan 1997-Jun 2007 were included. New users 
were defined as having no ALLO prescribed in the 1 yr prior to cohort entry. Cohort 
entry was defined by date of 1st ALLO claim. Adherence level was assessed by med-
ication possession ratio (MPR) and cumulative persistence rates by Kaplan-Meier 
analysis. Adjusted Cox regression models estimated rate ratio of ceasing ALLO. 
Logistic regression models established relation between non-adherence level and 
their determinants. Results: Of 2752 patients, mean age was 70 (63-76) yrs, 82% 
men. Close to 50% had ≥ 1 cardiovascular disease, dyslipidemia (33%), diabetes 
(21%), CKD (15%), and rheumatic disease (6.3%). Patients included users of low-dose 
aspirin (33%) and NSAIDs (42%). During the 1st yr, MPR was 71% and high adher-
ence (MPR ≥ 80%) was 57%. Persistence decreased to 47% after 1-yr follow-up. Non-
persistence was more likely in patients with rheumatic disease (by 25%) and in 
NSAID users (by 18%). For previous ALLO users, persistence was increased by 29%. 
Persistence was higher for intra-articular corticosteroid users (by 18%), patients 
who had had a prior use of ALLO (29%), users ≥ 7 medications (by 39%). Non-
adherence determinants were similar to those of non-persistence. cOnclusiOns: 
Barriers to persistence/adherence occur early during ALLO therapy. Adherence is 
key to determine success of many treatment approaches; greater attention may 
result in improved outcomes.
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Objectives: Biologics are drugs with a large economic burden for health care 
providers and should only be given to patients with a sever autoimmune disease 
like rheumatoid arthritis (RA), ankylosing spondylitis (AS) or psoriatic arthritis(PS). 
The aim of this study was to evaluate the prescription reality of biologics within 
these diagnoses. MethOds: To examine the prescription reality of biologics, 
prescriptions of a large German claims data base were evaluated. Demographic, 
prescription and diagnosis data was taken from 2007 to 2013 to identify the pre-
scription routine on a yearly basis. This study included 42,441 to 92,059 patients 
per year suffering from RA, PS or AS and their observed prescriptions of biologics. 
Patients were only included if they were fully observable in the specific year of 
analysis. Results: The underlying base population of the whole claims data base 
(n = 3,6m) is fairly comparable to the overall German population regarding age, 
gender, morbidity and mortality. In 2013 84,645 AS patients, 37,839 PS and 56,570 
RA patients could be observed, where 58,45% are female (mean age = 57,55 years). 
Overall, the prescription ratio of biologics increased from 1,61% in 2007 to 3,43% in 
2013. Concerning gender, no difference in the probability of biologics prescriptions 
could be observed (57,43 % of biologics patients were female). However, a sharp 
drop in the prescription of biologics for elderly patients is present (5,8% 30-39y; 
5,5%40-59y vs 3,1% 60-69; 1,74%70-79; < 0,65% 80+). In contrast to this result, 
patients with a disease combination receive biologics more frequently (MS+AS+PS: 
29,89% vs. AS: 5,96%, PS: 2,04%, RA:9,79%). cOnclusiOns: Although the frac-
tion of patients with biologics increased in the last years, old people seem to be 
obtained from outpatient drug prescriptions, hospital discharges and ambulatory care 
records collected from January 1, 2005 to December 31, 2008. The study was designed 
as a retrospective study cohort. Patients 60 years of age or older were included if at 
least one prescription for any antiosteoporotic drugs. had been filled in between 
January 1, 2006 and December 31, 2006. For each patient, the following characteristics 
were considered:gender, age, dosing regimen, previous treatments, previous frac-
tures, co-prescription of calcium/Vitamin D, spot therapy, switcher, comorbidity. The 
primary outcome of this study was persistence at one year; the secondary outcome 
was hospitalized osteoporotic fractures based on ICD-9 codes related osteoporotic 
fracture. Results: The final cohort consisted of a total of 7,862 patients, aged > 60 
years. Kaplan – Meier analysis showed that 3,733 patients (47.5%) were persistent 
with antiosteoporotic drugs after 1 year. In the logistic regression analysis adjusted 
for potential confounders odds of fracture were significantly lower for persistent 
patients (OR:0.79). Older patients were more likely to incur a fracture than younger 
[70-79 years(OR:1.52), ≥ 80 years (OR:2.49)]. The odds of fracture were significantly 
higher for patients with previous fractures in comparison with those without previous 
fractures (OR: 1.70). cOnclusiOns: The current analysis demonstrates a significant 
association between risk of fracture and persistence. Persistence to therapy with 
antiosteoporotic drugs is important for the effectiveness of osteoporosis treatment. 
Improving osteoporosis treatment compliance and persistence is an important chal-
lenge for clinicians and the society as a whole.
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Objectives: Argentinean health system is divided in 3 subsectors: Social Security 
(48%), Public (42%) & Private (10%). It is known that the public one is the one 
with the biggest gaps in terms of capabilities, infrastructure and budget capacity 
and the most fragmented (24 differents states without standarized procedures). 
However, no local data is available regarding the accessability to biologics for the 
treatment of Rheumatoid Arthritis. The aim of the study is to describe the actual 
picture of biologics availability in the public sector, rheumatologist perception 
about main barriers and finally, to describe potential solutions. MethOds: A sur-
vey to 200 rheumatologist (Rheumatologist population in the whole country is 
witihin 400 - 600) was sent using gForms with the aim to describe the avalability of 
synthetics DMARD, biologics DMARD and targeted synthetic DMARD (Tofacitinib); 
main barriers according rheumatologist perception and budget management was 
also assessed. Results: 80% of the rheumatologist expressed that biologics are 
not avaialble in the public sector as a regular treatment, just as an “exception”. 
Among these spontaneously availability Adalimumab, Rituximab, Etanercept and 
Tocilizumab were the most named. Surprisingly, synthetic (classic) DMARD like 
metotrexate is available with severe impairements in the delivery. Main barrier 
to obtain biologics according rheumatologist perception is the restrictive budget 
allocation in the Institution, followed by biologic prices. cOnclusiOns: The pre-
sent study is the first one regarding biologic availability in the public sector in 
argentina. Big gap is seen when talking about RA treatments, moreover when a 
biologic is prescribed. Potential solutions might be: differential prices for differents 
sector, centralized drug purchasing, well design copayments, and others to be 
descripted in the poster. Full references, questionnaire with other responses and 
potential solutions are to be described in the poster.
PMS119
AcceSS to BiologicAl therAPieS And conSuMPtion trendS in BoSniA 
And herzegovinA
Catic T
ISPOR Bosnia and Herzegovina Chapter, Sarajevo, Bosnia
Objectives: Biologics are used for treatment of different diseases from cancer to 
autoimmune diseases. According to IMS biologics share in total pharma market 
in 2002 was 11% and will reach 19-20% of market share in 2017. This class of drug 
bears high costs and this is the main reason of low access to these therapies in 
developing and low income countries. Due to the costs access to this therapeutics 
depends on public funding. We examined access and trends of consumption of 
novel biologics in Bosnia and Herzegovina. MethOds: Data on consumption of 
biologics was generated from official report on annual pharmaceutical expenditure 
published by State agency for medicines and medical devices. We covered 6-years 
period (2009-2014). Access to biologics depends on public funding and has direct 
impact on expenditure and these data have been taken from official reimbursement 
lists of Health Insurance Funds financing expensive medicines. Data on expenditure 
are represented in value (EUR) and analysis did not consider volume sales. Results: 
Market share of biologics in total B&H pharma-market in 2009 was 4% and increased 
to 8% in 2014 which is highly below global trend. Monoclonal antibodies for can-
cer are present at reimbursement lists from 2009 showing constant sales growth. 
Trastuzumab is most used biologic (1,9m€ in 2009 and 6,9m€ in 2014), followed by 
rituximab, sunitinib, sorafenib and bevacizumab. Impact of reimbursementis best 
shown in case of sunitinib and sorafenib with high sales increase reflecting medi-
cal need for these therapies. Imatinib sales significantly dropped after biosimilar 
introduction into the market in 2013. Lapatinib and nilotinib had been introdudec 
into the market in 2010 and palivizumab and adalimumab in 2011 showing constant 
sales growth cOnclusiOns: Access to novel biologic depends on public funding 
and there is significant need to these therapies . Biosimilar introduction into market 
can significantly improve access to these therapies and decrease costs
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tions between the patient numbers by months in physiotherapy care and the 
prevalence of fracture development. The authors suggest structuring the health 
care system and distributing resources to follow the needs supported by our 
findings.
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Objectives: Gout, a chronic inflammatory arthritis, can result in extensive medi-
cal problems due to painful flares and joint damage resulting from the build-up of 
tophi (deposits of uric acid crystals). The prevalence of gout is rising, which is likely 
to increase the burden of the disease. We determined the current cost impacts 
of gout and identified key disease burden factors. We also aimed to highlight 
data gaps for further investigation. MethOds: A systematic literature review was 
conducted using the MEDLINE database and The Cochrane Library. Articles pub-
lished in English between January 2000 and July 2014 that reported the economic 
burden (in terms of either direct or indirect costs) were identified, and patient 
and cost data were collated, with key themes and data gaps identified. Results: 
Of the 323 studies identified, 13 primary studies were relevant to the economic 
burden of gout. Key variables included serum uric acid levels, presence of tophi 
and number of flares, which resulted in high healthcare resource use that was 
frequently attributed to hospitalisation and inpatient stay. The incremental direct 
cost of gout was reported to be up to US$21,467 per annum, in cases where patients 
were experiencing regular acute flares with the presence of tophi. cOnclusiOns: 
Patient-level costs associated with the treatment and clinical management of 
gout can be substantial, depending on disease severity. The identified studies 
were dominated by direct cost analyses; only three studies specifically considered 
indirect costs. There was a paucity of non-US data, and there was a lack of pub-
lished studies estimating the population-wide cost. Despite the limited published 
data, the review identified a growing number of publications in this area in the 
last 5 years, suggesting healthcare decision makers’ increasing awareness of the 
wider impacts of gout.
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Objectives: To compare the total value of payer’s expenditures on Cimzia (cer-
tolizumab pegol) and RoActemra (tocilizumab) in patients with severe rheumatoid 
arthritis estimated in the manufacturers’ Budget Impact Analyses (BIAs) submitted 
with the reimbursement applications to AOTMiT and actual expenditures of the 
National Health Fund (NHF). MethOds: Annual public payer’s expenditures esti-
mated in manufacturers’ BIAs for Cimzia and RoActemra and actual expenditures 
reported by the NHF were compared. RSSs were not taken into account. Analysed 
drugs were chosen on the basis of the same indication and financing through 
the same therapeutic programme in Poland. Actual expenditures and population 
size were taken from the financial reports of the NHF for the first and second 
year (actual data on 11 months for expenditures were extrapolated to one year) 
of reimbursement for each drug. Results: For drugs Cimzia and RoActemra in 
patients with severe rheumatoid arthritis, the sum of total expenditures estimated 
in BIAs submitted with the reimbursement applications was 18,04 million PLN in 
the first year and 28,47 million PLN in the second year, and they were lower than 
the actual expenditures reported by the NHF: 20,03 million PLN and 36,51 million 
PLN, respectively. The expenditures estimated in BIAs were underestimated by 10% 
in the first year of reimbursement and 22% in the second year of reimbursement. 
Population size estimated in BIAs in comparison to its actual size from the NHF 
reports was underestimated by 61% in the first year and 57% in the second year 
of reimbursement. cOnclusiOns: In the case of drugs chosen for this analysis, 
total payer’s expenditures estimated in BIAs submitted with the reimbursement 
applications were underestimated in comparison to the real life expenditures of 
the NHF in Poland.
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Objectives: Osteoporosis is one of the commonest bone diseases in which bone 
fragility is increased. There are several possibilities for the prevention of primary, 
secondary and tertiary osteoporosis but until now they have not been promoted 
enough and bone fragility is thought about only after the onset of a fracture (ter-
tiary prevention). Preventative strategies against osteoporosis can be aimed at 
either optimizing the peak bone mass obtained, or reducing the rate of bone 
loss. Optimization of peak bone mass may be more amenable to public health 
strategies. MethOds: A group of patients over 50 year old that has been treated 
with medicines included in the AIFA Note 79 during a period of 5 years is studied 
in comparison with a similar group that has not been treated with medicines 
included in the AIFA Note 79 for the same period time. For both groups are also 
extracted inpatient and outpatient medical records and medicine prescriptions. 
Only patients treated for at least three years are considered significant. To avoid 
confounding the resulting data were standardized and stratified. Results: The 
total expenditure for patients compliant with therapy who have had access to the 
hospital is less than twenty-eight percent compared to the total expenditure for 
patients not receiving therapy or not compliant. cOnclusiOns: Osteoporosis is 
undersupplied, even though they have a higher charlson-comorbidity index. Still, 
this study may not clarify whether this is due to costs or patient and physician 
preference.
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Objectives: The aim of this study is to perform gender specific analysis regard-
ing the persistence to antiosteoporotic drugs by using administrative data-
bases. MethOds: The data used for this study were obtained from outpatient 
drug prescriptions, hospital discharges and ambulatory care records collected 
from January 1, 2005 to December 31, 2008. The study was designed as a retrospec-
tive study cohort. Patients 60 years of age or older were included if at least one 
prescription for any antiosteoporotic drugs had been filled in between January 
1, 2006 and December 31, 2006. Persistence was defined as the length of time 
in days from the date of the index prescription to the date of discontinuation 
therapy. Discontinuation was evaluated by using the gap method. Results: 
The final cohort consisted of a total of 7,867 patients (87.2% women). The mean 
patient age for both genders at the index date was 74.5 years. About one-fifth of 
all subjects had experienced with spot therapy, but men were more likely than 
women to have a spot therapy experience (45.4% vs. 14.5%). Approximately 6% 
of all included patients were switchers: Switching rates were highest for males 
(18.9%) and lower for female (4.4%). The crude analysis of long-term gender per-
sistence showed a significant difference between women and men users: the 
relative number of persistence patients after 1 year was 66.4% in men and 44.7% 
in women. The Kaplan Meier plots of time to persistence start to differ for men 
vs women approximately 60 days after treatment start. cOnclusiOns: Gender 
differences in medication taking behaviour is a relevant issue in drug utilization 
studies. Our analysis showed that women are more likely to be non-persistent 
than men in osteoporosis ttherapy.
PMS124
nuMBer of oSteoPoroSiS PAtientS with PAthologicAl frActureS By 
gender in outPAtient cAre in the light of PhySiotherAPy cAre in 
hungAry
Molics B1, Endrei D1, Rátgéber L2, Gyuró M1, Sebestyén A3, Juhász R1, Elmer D1, Boncz I1, 
Péter I4, Juhász K3, Járomi M1
1University of Pécs, Pécs, Hungary, 2Ratgeber Academia, Pécs, Hungary, 3National Health 
Insurance Fund Administration, Pécs, Hungary, 4Zsigmondy Vilmos SPA Hospital, Harkány, 
Hungary
Objectives: The aim of our study is to determine the number of osteoporosis 
patients with pathological fractures by gender in outpatient care based on physi-
otherapy activities. MethOds: The data come from the financial data base of the 
National Health Insurance Fund Administration (in Hungarian: OEP) involving 
the year of 2013. The activity list was provided by the rulebook on the application 
of the activity code list in out-patient care. The osteoporosis with pathological 
fractures is listed in the International Classification of Diseases (ICD) with code 
of M80. Population distribution was taken into account on the basis of the data 
of the Central Statistical Office from January 1st 2013. Results: Based on 151 
physiotherapy activities, the annual patient numbers accounted for 39725 per-
sons in the total population. The patient numbers accounted for 2544 persons 
for males and 37181 persons for females (10,000 per capita the patient num-
bers were 40 persons for the total population, 5 persons for males and 72 for 
females). cOnclusiOns: The higher patient numbers for females can be clearly 
associated with the prevalence of the basic disease. The total value for the patient 
numbers by months is higher caused by the aftercare of the same patients that 
still lasts in the following month. The authors suggest structuring the health 
care system and distributing resources to follow the needs supported by our 
findings.
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Objectives: The aim of our study is to determine the number of osteoporosis 
patients with pathological fractures by months in outpatient care based on physi-
otherapy activities. MethOds: The data come from the financial data base of 
the National Health Insurance Fund Administration (in Hungarian: OEP) covering 
the year of 2013. The activity list was provided by the rulebook on the applica-
tion of the activity code list in out-patient care. The osteoporosis with patho-
logical fractures is listed in the International Classification of Diseases (ICD) 
with code of M80. Results: Based on 151 physiotherapy activities, the annual 
patient numbers accounted for 85142 persons in the total population by months. 
The patient numbers accounted for 5063 persons for males and 80079 persons 
for females. The patient numbers were 86 persons for the total population, 11 
persons for males and 154 for females per 10,000 capita. The patient numbers 
above average by months could be found in the spring and autumn months (aver-
age: population= 7095, males= 421, females= 6673). cOnclusiOns: The higher 
patient numbers for females can be clearly associated with the prevalence of 
the basic (osteoporosis) disease. It would be interesting to examine the correla-
